Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Key Highlights
- ➤Maria Ostrovsky appointed Candel general counsel, effective November 3, 2026
- ➤Candel plans aglatimagene BLA submission in fourth quarter of 2026
- ➤Ostrovsky brings 20 years of life sciences legal experience
- ➤Candel is preparing capabilities for potential aglatimagene commercialization
Expert Statements
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“Maria brings a highly relevant combination of legal, compliance, global product launch and strategic transaction experience”
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“She has supported oncology launches in the United States and globally, built a healthcare compliance program at a commercial-stage biotech, and helped guide acquisition diligence, post-merger integration and international operations.”
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“As we prepare for our planned BLA submission and potential commercialization of aglatimagene, if approved, Maria will help us build scalable legal, governance and compliance capabilities for Candel’s next stage of growth.”
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“I am delighted to welcome her to our leadership team.”
Maria Ostrovsky, General Counsel of Candel Therapeutics
“Candel is at an inflection point, with its first planned BLA submission ahead and a pipeline spanning several difficult-to-treat cancers”
Maria Ostrovsky, General Counsel of Candel Therapeutics
“I am excited to join the leadership team and help establish the legal and compliance foundation needed to support Candel’s continued growth, potential transition toward commercialization and mission to bring new treatment options to patients.”
* Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel prepares for its planned Biologics License Application (BLA) submission and potential commercialization NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer.
Ms. Ostrovsky joins Candel at a pivotal stage in the Company’s evolution, as it advances its clinical pipeline, prepares for a planned BLA submission for aglatimagene besadenovec (aglatimagene) in intermediate- to high-risk localized prostate cancer in the fourth quarter of 2026, and builds the capabilities needed to support potential commercialization, if approved.
Get started
Create a free account to read the full story.